Skip to main content

Day: October 4, 2021

Arbor Realty Trust, Inc. Announces Pricing of Public Offering of Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

UNIONDALE, N.Y., Oct. 04, 2021 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (the “Company”) (NYSE:ABR) announced today that it has priced the public offering of 7,000,000 shares of its 6.25% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (the “Series F Preferred Stock”), liquidation preference $25.00 per share, for gross proceeds of $175 million, before deducting underwriting discounts and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of the Series F Preferred Stock to cover over-allotments, if any. The Company intends to file an application to list the Series F Preferred Stock on the NYSE under the symbol “ABR PrF” and, if approved, expects trading to commence within 30 days after the initial issuance of the Series F...

Continue reading

OrthoPediatrics Corp. Continues Support of Autumn Surgical Society Meetings

WARSAW, Ind., Oct. 04, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support for the American Academy for Cerebral Palsy and Developmental Medicine (“AACPDM”), which will take place virtually October 6th – 9th. In addition to its Platinum-level sponsorship, OrthoPediatrics will provide scholarships, educational support, and a virtual exhibit for AACPDM showcasing the Company’s products, and live chat sessions with surgeon customers and members of the OrthoPediatrics business teams at the 75th Annual Meeting. The Company continues its leadership role in supporting multiple avenues of education, having recently attended the Annual Scoliosis Research Society (“SRS”) meeting...

Continue reading

LifeMD Announces Closing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) — LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company today announced the closing of its previously announced underwritten registered public offering of 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), with a total liquidation preference of $35,000,000. In connection with this offering, the Company has granted the underwriters a 30-day option to purchase an additional 210,000 shares of Series A Preferred Stock at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds after deducting the underwriting discounts and commissions, the structuring fee and estimated offering expenses payable by the...

Continue reading

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress

Continuing filgotinib 200mg among induction non-responders at week 10 resulted in clinical benefits for ulcerative colitis (UC) patients in the long-term extension study (LTE)Treatment with filgotinib 200mg resulted in clinically meaningful improvements in health-related quality of life (HRQoL) measures by week 58 among patients with UCMechelen, Belgium; 4 October 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies, which are part of the investigational clinical program for filgotinib, for the treatment of patients with moderately to severely active UC. These analyses showed clinical benefits of continued dosing with filgotinib 200mg, an oral once-daily JAK1 preferential inhibitor, in patients who did not respond at week 10. Separately,...

Continue reading

CorMedix Inc. Announces Executive Leadership Changes

BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced changes to its executive leadership team. Khoso Baluch is retiring from his role as Chief Executive Officer, effective October 4, 2021, and has also resigned from the Company’s Board of Directors. John Armstrong, EVP for Technical Operations, is retiring from CorMedix, effective October 4, 2021. The Board has appointed Matt David, M.D., CorMedix’s EVP and Chief Financial Officer, as interim Chief Executive Officer, effective immediately. Dr. David will continue to hold his position of Chief Financial Officer. The Board is initiating a search process with a leading executive...

Continue reading

Augmedix Announces Launch of Underwritten Offering

SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) — Augmedix, Inc. (OTCQX: AUGX) (“Augmedix”), a leading provider of virtual medical documentation and live clinical support, today announced the launch of its underwritten offering of $40,000,000 of shares of its common stock. Augmedix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock that are sold in the offering. Augmedix has applied to list its common stock on the Nasdaq Capital Market under the ticker symbol “AUGX.” William Blair & Company, L.L.C. is acting as sole active bookrunner for the offering. B. Riley Securities, Inc. is acting as a passive bookrunner and The Benchmark Company, LLC and Lake Street Capital Markets, LLC are acting as co-managers. The proposed offering will be made only by means of a prospectus....

Continue reading

LifeMD Announces Closing of Public Offering of Common Stock and Exercise of the Underwriters’ Option

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) — LifeMD, Inc. (the “Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced the closing of its previously announced underwritten registered public offering of 3,833,334 shares of its common stock, par value $0.01 per share, which includes 500,000 shares of common stock issued upon the exercise in full of the underwriter’s option to purchase additional shares of common stock. The Company intends to use the net proceeds after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, but before repayment of debt, of approximately $21.4 million to repay a portion of its indebtedness and the remaining net proceeds for working capital and general corporate purposes including, but not limited to, new patient customer...

Continue reading

Augmedix Announces Preliminary Third Quarter 2021 Financial Results

SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) — Augmedix, Inc. (OTCQX: AUGX), a leading provider of virtual medical documentation and live clinical support, today announced preliminary unaudited financial and operational results for the three months ended September 30, 2021. “We executed well across our initiatives and the strong bookings momentum and accelerating top line growth experienced during the previous four quarters carried into the third quarter. This quarter was marked by meaningful customer and operational achievements, and was highlighted by the execution of our strategic partnership with Medical Advantage and our recently announced partnership with Google to integrate Google Cloud’s medical automatic speech recognition technology into our natural language processing models to accelerate our ability to scale efficiently,”...

Continue reading

Precision Drilling Corporation 2021 Third Quarter Results Conference Call and Webcast

CALGARY, Alberta, Oct. 04, 2021 (GLOBE NEWSWIRE) — Precision Drilling Corporation (“Precision”) intends to release its 2021 third quarter results before the market opens on Thursday, October 21, 2021 and has scheduled a conference call and webcast to begin promptly at 12:00 Noon MT (2:00 p.m. ET) on the same day. The conference call dial in numbers are 844-515-9176 or 614-999-9312 (International) or a live webcast is accessible on our website at www.precisiondrilling.com. An archived version of the webcast will be available for approximately 60 days. An archived recording of the conference call will be available approximately one hour after the completion of the call until October 25, 2021 by dialing 855-859-2056 or 404-537-3406, passcode 8393532. About Precision Precision is a leading provider of safe and environmentally responsible...

Continue reading

Lamar Advertising Company to Release Third Quarter Ended September 30, 2021 Operating Results

BATON ROUGE, La., Oct. 04, 2021 (GLOBE NEWSWIRE) — Lamar Advertising Company (Nasdaq: “LAMR”) will release its third quarter ended September 30, 2021 earnings report before the market opens on Wednesday, November 3, 2021. Lamar will host a conference call on Wednesday, November 3, 2021 at 8:00 a.m. (Central time) to discuss the Company’s results and answer questions relating to company operations. Instructions for dialing into Lamar’s conference call are provided below:All Callers: 1-334-777-6991 or 1-800-338-4880Passcode: 36341506     Replay: 1-334-323-0140 or 1-877-919-4059Passcode: 55208290     Available through Wednesday, November 10, 2021 at 11:59 p.m. Eastern time   Live Webcast:  www.lamar.com    Webcast Replay: www.lamar.com     Available through Wednesday, November 10, 2021 at 11:59...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.